The Boston Scientific-sponsored trials, dubbed Perseus, compared its newly designed Taxus Element stent, based on a platinum chromium alloy, with its older Taxus Express stent, which has been ...

Global medical device maker Boston Scientific received CE approval for its REBEL Platinum Chromium coronary stent system last week, paving the way for its sale in Europe. The REBEL bare metal ...

Those include a suit brought by Cordis related to Boston Scientific’s Express, Taxus, Taxus Liberte and Promus stents, and another case related to its NIR stent system.

Ltd from Synergy Innovation Co., Ltd. This latest investment is aimed at broadening Boston Scientific’s stent portfolio within the broader MedSurg business globally. The purchase price has been ...

BOSTON (CBS.MW) -- Boston Scientific said Thursday it is recalling ... of both its drug-coated Taxus and bare-metal Taxus Express stent systems. Thursday's recall brings that number up to about ...

S&P Equity Research said the risk of blood clots in patients treated with drug-coated stents remains in-line with the data presented in Boston Scientific's clinical trials prior to gaining ...

"With the addition of the Express SD Renal Stent, Boston Scientific can now offer customers the industry's leading portfolio of products for endovascular treatment of this disease." Renal artery ...

NEW YORK (MarketWatch) -- Boston Scientific Corp. Thursday unveiled a program offering patients a Taxus Express2 stent system at no additional charge if the patient requires a re-intervention due ...

Boston Scientific plans to fully acquire stent developer Veniti—which it already owns 25% of—by buying up the remaining stake in the startup for $108 million upfront, plus up to $52 million ...

Boston Scientific Corp. (NYSE: BSX) has recalled more than 500 stent systems in its second recall for a potentially life-threatening defect to be disclosed this week. The stent may fail to deploy ...

A heart stent manufactured by Boston Scientific Corp. and expecting approval for U.S. sales is backed by flawed research despite the company's claims of success in a clinical trial, according to a ...